Roche Strengthens Its Bet Against the “Superbug”By Ion Jauregui – Analyst at ActivTrades
Zosurabalpin: A New Hope Against Antimicrobial Resistance
Swiss pharmaceutical giant Roche (SWX: ROG) has just taken a major step forward in the fight against bacterial resistance: its new antibiotic zosurabalpin is entering Phase 3 clinical trials. The co
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
1.8 USD
9.40 B USD
68.69 B USD
5.52 B
About ROCHE I
Sector
Industry
CEO
Thomas Schinecker
Website
Headquarters
Basel
Founded
1896
FIGI
BBG00JRY9DR7
Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Related stocks
Roche vs. Novo Nordisk: Who will suffer the Weight Loss?Roche (ticker: ROG.SW) is losing ground on the stock due to the side effects of its new weight loss pill, CT-996, which is still in the testing phase. After a rally that boosted its shares 40% between May and September, the Swiss drugmaker has seen an 11% drop in its shares in September alone, inclu
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896
Roche: Ready for 120% Growth?We're trying something with Roche here, where we think that we are currently in Wave (5), having recently completed Wave (4). This assessment is better visualized on the daily chart. Hence, we should maintain the 61.8% level for this Wave 4. Anything below would statistically be too low, while above
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here.
Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma.
There were only 3 pull backs greater than 30% in the history of the stock.
2002 ~ 2003: -45.33%
2006 ~ 2011: -52.40%
2014 ~ 2018: -30.24%
2022 ~ present: -44.89%
It is at the support z
Roche HoldingsThis is one of those companies you can't afford not to look into. Roche is one of the world's largest biotech companies and a global leader in pharmaceuticals and diagnostics. This leading position translates to strong market share, revenue, and profitability. The company operates across various seg
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
CHGCY5698948
Roche Holdings, Inc. 5.265% 13-NOV-2026Yield to maturity
—
Maturity date
Nov 13, 2026
CHGCY5885612
Roche Holdings, Inc. 4.592% 09-SEP-2034Yield to maturity
—
Maturity date
Sep 9, 2034
A3LRKK
ROCHE KAPITALMARKT AG 2023-15.09.33Yield to maturity
—
Maturity date
Sep 15, 2033
CHGCY5141501
Roche Holdings, Inc. 0.991% 05-MAR-2026Yield to maturity
—
Maturity date
Mar 5, 2026
CHGCY5885611
Roche Holdings, Inc. 4.592% 09-SEP-2034Yield to maturity
—
Maturity date
Sep 9, 2034
CHGCY5698672
Roche Holdings, Inc. FRN 13-NOV-2026Yield to maturity
—
Maturity date
Nov 13, 2026
A3K88A
ROCHE KAPITALMARKT AG 2022-23.09.32 GUARANTEEDYield to maturity
—
Maturity date
Sep 23, 2032
CHGCY4391962
Roche Holdings, Inc. 7.0% 01-MAR-2039Yield to maturity
—
Maturity date
Mar 1, 2039
CHGCY5698942
Roche Holdings, Inc. 5.338% 13-NOV-2028Yield to maturity
—
Maturity date
Nov 13, 2028
CHGCY4184535
Roche Holdings, Inc. 4.0% 28-NOV-2044Yield to maturity
—
Maturity date
Nov 28, 2044
CHGCY5317643
Roche Holdings, Inc. 1.93% 13-DEC-2028Yield to maturity
—
Maturity date
Dec 13, 2028
See all 0TDF bonds
Curated watchlists where 0TDF is featured.